CALC stock forecast, quote, news & analysis

Key Takeaways

• CalciMedica (CALC) shares fell roughly 27% over the trailing 30 days, sliding from about $2.32 to near $1.70.
• The decline extended a prolonged multi-month downtrend and followed a 1-for-5 reverse stock split completed in late August.
• Losses came despite a Buy initiation from Guggenheim and FDA alignment on the Phase 2b Auxora trial design, underscoring lingering financing and dilution concerns.
• As a pre-revenue, clinical-stage biotechnology company, CALC remains highly sensitive to cash runway, clinical milestones, and broader risk appetite.

CalciMedica (CALC) Company Overview and Market Position

CalciMedica, Inc. is a clinical-stage biopharmaceutical company headquartered in La Jolla, California. The company develops therapies built around calcium release-activated calcium (CRAC) channel inhibition, a mechanism designed to modulate immune response and protect against tissue cell injury in serious inflammatory and immunologic conditions. Its lead candidate, Auxora (active compound zegocractin, formerly CM4620), is being studied in acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury. The company is also advancing CM5480, an oral CRAC-channel inhibitor, as a potential treatment for pulmonary arterial hypertension (PAH).

CalciMedica has no approved products and generates no product revenue, which places it firmly among early-stage, development-driven biotech names. With a small market capitalization and a focused clinical pipeline, the stock is followed primarily by investors tracking data catalysts, regulatory milestones, and the company's ability to fund its programs.

CalciMedica (CALC) Stock Price Performance: Last 30 Days vs. Quarter

Over the trailing 30 days, CALC declined approximately 27%, moving from a closing level near $2.32 to about $1.70. The move was characterized by steady downward pressure rather than a single sharp event, with the shares setting progressively lower levels through September.

The quarterly trend is even more pronounced. On a split-adjusted basis, the stock traded near $4.90 in late June before sliding to roughly $1.70 by late September — a decline of roughly 65% over the period. This multi-month downtrend reflects persistent selling in the shares alongside the company's limited cash-generating capacity as a pre-revenue developer.

What Drove CALC Stock Price in the Last 30 Days

Several factors contributed to the recent decline. The company completed a 1-for-5 reverse stock split in late August, a step listed companies often take to raise their per-share price and address exchange listing standards. Following the split, the shares continued to trade lower, indicating that the corporate action did not reverse the underlying selling pressure.

Fundamentals also remained a headwind. CalciMedica reported no product revenue and posted a net loss, consistent with its clinical-stage status, while carrying a modest cash balance relative to its development needs. These conditions can keep dilution concerns and financing overhang at the forefront of investor sentiment.

Notably, the decline occurred alongside constructive developments. Guggenheim initiated coverage with a Buy rating, citing the potential of CM5480, and the company announced alignment with the U.S. Food and Drug Administration on endpoints and patient population for its Phase 2b Auxora trial. That the stock still fell despite these updates highlights the weight of broader risk-off sentiment toward speculative, pre-revenue micro-cap biotechs and thin trading conditions.

What Drove CALC Stock Performance Over the Last Quarter

The quarterly decline reflects a broader narrative of a clinical-stage company contending with both execution and capital-market realities. The company reported its second-quarter 2026 results in August with ongoing operating losses typical of its stage. The reverse stock split introduced additional technical and psychological pressure, as post-split shares in underperforming small caps frequently continue to drift lower.

More broadly, small- and micro-cap biotechnology names have faced a challenging environment, with investors demanding clearer paths to clinical data and financing stability. For CalciMedica, the absence of near-term revenue and the dependence on future capital raises kept the shares in a sustained downtrend despite select positive pipeline news.

Trending AI Robots

Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that are actively trading across the market. While Tickeron offers hundreds of AI trading bots covering thousands of tickers, only the top-performing and most relevant bots are featured in this section. These bots vary in strategy, timeframe, and performance metrics, giving traders a range of data-driven approaches to evaluate. For investors monitoring volatile names such as CALC, these tools can provide an additional, quantitative perspective on market activity. Explore the Trending AI Robots page to review the currently featured bots and their performance.

CALC Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, investors are likely to focus on the company's clinical execution and balance-sheet durability. Key areas to monitor include enrollment and data updates from the CARPO Phase 2b trial in acute pancreatitis, the investigator-initiated CRSPA study in pediatric asparaginase-induced pancreatic toxicity, and progress on CM5480 in pulmonary arterial hypertension. The company has indicated that an update on the CRSPA program is expected during 2026.

Financing remains a central consideration, as CalciMedica's cash position relative to its development timeline could necessitate additional capital raises. Upcoming quarterly results, expected around November 2026, and any changes in analyst coverage will also shape sentiment. As with all clinical-stage biotechs, outcomes remain inherently uncertain, and investors should weigh both pipeline opportunity and liquidity risk.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations